Abstract:There is no consensus regarding optimal dosing of vancomycin in term or preterm neonates. Various available dosing recommendations are based on age, kidney function and/or body weight to define a starting dose. Our objectives were (i) to develop a comprehensive population PK model of vancomycin in a large cohort of neonates and (ii) to evaluate and compare the performances of current dosing approaches with respect to target attainment, using simulations based on our model. This will serve the purpose to recommend the best dosing approaches among existing regimens in the early and later phases after treatment initiation as a complementary approach to therapeutic drug monitoring (TDM). A total 405 neonates provided 1831 vancomycin concentrations measured during routine TDM. A one-compartment model with linear elimination incorporating covariates such as age, kidney function and body weight was developed (NONMEM (R)). The final model was applied to simulate in our population vancomycin exposure resulting from 20 dosing guidelines identified in the literature. Proportions of patients within and above target exposure were used as a performance measure. Target attainment meant area under the curve/ minimal inhibitory concentration (AUC(24)/MIC) ratio of 400-700 h and trough concentration of 10-20 mg/L, both on days 1 and 7. Most current vancomycin dosing regimens fail to ensure target attainment in a majority of neonates. Insufficiently dosed regimens should be avoided, especially in centers with widespread coagulase negative Staphylococci. Adding a loading dose to simple regimens is best recommended to increase the proportion of early target attainment. Complex regimens seem to marginally improve exposure. Optimisation of efficacy while minimizing toxicity of vancomycin in neonates is needed. The application of a simple dosing regimens like NNF7 or the Neofax Hi-Dose regimens, with a 25 mg/kg loading dose for severe infections, or the SmPC regimen should be recommended to ensure the highest proportion of target attainment after 24 h. TDM should then be carried out, to account for residual unexplained variability in vancomycin elimination.

O26 Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young Infants

Population Pharmacokinetic Meta-Analysis of Individual Data to Design the First Randomized Efficacy Trial of Vancomycin in Neonates and Young Infants

Optimization of Vancomycin Initial Dosing Regimen in Neonates Using an Externally Evaluated Population Pharmacokinetic Model

Optimisation of Vancomycin Exposure in Neonates Based on the Best Level of Evidence.

Clinical Utility and Safety of a Model-Based Patient-Tailored Dose of Vancomycin in Neonates.

External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: the Transferability of Published Models to Different Clinical Settings.

Predictive Performance of Pharmacokinetic Model-Based Virtual Trials of Vancomycin in Neonates: Mathematics Matches Clinical Observation

Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing

Use of Machine Learning for Dosage Individualization of Vancomycin in Neonates

Pharmacodynamics of Vancomycin for CoNS Infection: Experimental Basis for Optimal Use of Vancomycin in Neonates.

Vancomycin Continuous Infusion in Neonates: Dosing Optimisation and Therapeutic Drug Monitoring

How to use vancomycin optimally in neonates: remaining questions

Variation in vancomycin dosing and therapeutic drug monitoring practices in neonatal intensive care units

Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration.

Population pharmacokinetics and dosing optimization of vancomycin in infants, children and adolescents with augmented renal clearance

Population pharmacokinetic analysis for dose regimen optimization of vancomycin in Southern Chinese children

Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease.

External Evaluation of Vancomycin Population Pharmacokinetic Models at Two Clinical Centers

Index for the appropriate vancomycin dosing in premature neonates and infants

A simulation study to assess the influence of population pharmacokinetic model selection on initial dosing recommendations of vancomycin in neonates

Population Pharmacokinetics of Vancomycin in Chinese Infants